Class: Tricyclic compound Imipramine Hydrochloride
- Tablets 10 mg
- Tablets 25 mg
- Tablets 50 mg
- Capsules 75 mg
- Capsules 100 mg
- Capsules 125 mg
- Capsules 150 mg
Inhibits reuptake of norepinephrine and, to a lesser degree, serotonin in CNS.
T max is 2 to 4 h. Steady state is reached in 2 to 5 days.
More than 90% is protein bound. Lipid soluble.
Significant first pass effect. Metabolism occurs in liver. Active metabolite is desipramine.
The t ½ is 11 to 25 h.
2 to 4 weeks.
Indications and Usage
Relief of symptoms of depression; treatment of enuresis in children 6 yr and older.
Treatment of chronic pain, panic disorder, eating disorders (bulimia nervosa), and facilitation of cocaine withdrawal.
Hypersensitivity to any tricyclic antidepressant. Generally not to be given in combination with or within 14 days of treatment with MAO inhibitor or during acute recovery phase of MI; cross-sensitivity may occur among the dibenzazepines.
Dosage and AdministrationDepression
Use parenterally only in patients who are not able or not willing to take oral medication. Give via IM route. Do not administer IV. Up to 100 mg/day in divided doses may be given IM. Switch to oral as soon as possible.Adults
PO 100 to 300 mg/day, in divided doses or once daily at bedtime.Elderly & Adolescents
PO 30 to 40 mg/day; may increase up to 100 mg/day.Children
PO 1.5 mg/kg/day in divided doses; up to maximum of 5 mg/kg/day.Childhood Enuresis (6 yr)
PO 25 mg/day given 1 h before bedtime; if response unsatisfactory after 1 wk, may increase to 50 mg in children younger than 12 yr of age. Children older than 12 yr of age may receive 75 mg/night. Do not exceed 2.5 mg/kg/day.
Carbamazepine levels may increase; imipramine levels may decrease.Cimetidine, fluoxetine
May cause increased imipramine blood levels and effects.Clonidine
May result in hypertensive crisis.CNS depressants
Depressant effects may be additive.Dicumarol
Anticoagulant actions may increase.Guanethidine
Hypotensive action may be inhibited.MAO inhibitors
May cause hyperpyretic crises, severe convulsions, and death when given with imipramine.Sympathomimetics
Pressor response may be decreased by indirect-acting sympathomimetics and increased by direct-acting ones.
Laboratory Test Interactions
None well documented.
Orthostatic hypotension; hypertension; tachycardia; palpitations; arrhythmias; ECG changes; stroke; heartblock; CHF.
Confusion; hallucinations; delusions; nervousness; restlessness; agitation; panic; insomnia; nightmares; mania; exacerbation of psychosis; drowsiness; dizziness; weakness; numbness; extrapyramidal symptoms; emotional lability; seizures; tremors.
Rash; pruritus; photosensitivity reaction; dry skin; acne; itching.
Nasal congestion; tinnitus; conjunctivitis; mydriasis; blurred vision; increased IOP.
Nausea; vomiting; anorexia; GI distress; diarrhea; flatulence; peculiar taste in mouth; dry mouth; constipation.
Impotence; sexual dysfunction; nocturia; urinary frequency; UTI; vaginitis; cystitis; dysmenorrhea; amenorrhea; urinary retention and hesitancy.
Bone marrow depression including agranulocytosis; eosinophilia; purpura; thrombocytopenia; leukopenia.
Elevation or depression of blood sugar.
Pharyngitis; rhinitis; sinusitis; laryngitis; coughing.
Category D .
Excreted in breast milk.
Safety and efficacy of imipramine as temporary adjunctive therapy for nocturnal enuresis in pediatric patients younger than 6 yr have not been established; chronic use in patients 6 yr and older has not been established. Do not exceed 2.5 mg/kg/day.
Special Risk Patients
Use with caution in patients with history of seizures, urinary retention, ureteral spasm, angle-closure glaucoma or increased IOP, conduction disorders, with hyperthyroid or those receiving thyroid medication, hepatic or renal impairment, schizophrenia or paranoia.
Patients should use caution while performing tasks requiring alertness.
Use with extreme caution in patients with cardiovascular disorders. These patients require cardiac surveillance at all dose levels of the drug.
Confusion, agitation, hallucinations, seizures, status epilepticus, clonus, choreoathetosis, hyperactive reflexes, positive Babinski sign, coma, cardiac arrhythmias, renal failure, flushing, dry mouth, dilated pupils, hyperpyrexia.
- Warn patient of risk of seizure.
- Tell female patient to inform health care provider if becoming or intending to become pregnant.
- Explain that it may be several weeks before a response is noticed.
- Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
- Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
- Caution patient to avoid exposure to sunlight and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
- Teach patient to avoid sudden position changes to prevent orthostatic hypertension.
- Inform patient that dizziness, dry mouth (suggest taking frequent sips of water, sucking on ice chips, or sugarless hard candy or chewing sugarless gum), drowsiness, or constipation may occur, but that these side effects often subside with time.
- Instruct patient to report all problems to health care provider, including dizziness, drowsiness, dry mouth, constipation, or weight gain.
Copyright © 2009 Wolters Kluwer Health.
More Imipramine resources
- Imipramine Prescribing Information (FDA)
- imipramine MedFacts Consumer Leaflet (Wolters Kluwer)
- imipramine Advanced Consumer (Micromedex) - Includes Dosage Information
- imipramine Concise Consumer Information (Cerner Multum)
- Imipramine Hydrochloride Monograph (AHFS DI)
- Tofranil Prescribing Information (FDA)
- Tofranil-PM Prescribing Information (FDA)
- Tofranil-PM MedFacts Consumer Leaflet (Wolters Kluwer)